This eBook summarizes several key technological decision points to guide institutions and companies along the path to clinic-ready, gene-edited MSCs. One of these major decisions involves the intracellular delivery modality for the gene editor and template. Learn how efficient transduction and transfection of gene editors into MSCs could prime your clinical pipeline with the next generation of cellular therapy candidates. Authored by Jon Carson, PhD, Strategic Marketing Manager
Genome-Editing-of-MSCs_v1

RoosterBio, Inc. is a privately held cell manufacturing platform company focused on accelerating the development of a sustainable regenerative medicine industry, one customer at a time. Our products are high volume, affordable, and well-characterized adult human mesenchymal stem/stromal cells (hMSCs) paired with highly engineered media systems. We have simplified and standardized how stem cells are purchased, expanded, and used in development, leading to marked time and costs savings for customers. RoosterBio's innovative products are ushering in a new era of productivity and standardization to the field, accelerating the road to discovery in Regenerative Medicine.

For more information on RoosterBio, please visit our website.

To learn more about hMSCs and how to scale up your hMSC manufacturing, check out the RoosterBlog.